March 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb's combination treatment ...

Frontline nivolumab plus AVD reduced risk of progression or death by 58% versus brentuximab vedotin plus AVD (PFS HR, 0.42) in advanced-stage classical Hodgkin lymphoma. CA209-8UT randomized 994 ...

The FDA has approved the combination of nivolumab plus chemotherapy as first-line treatment for certain patients with stage III or IV classical Hodgkin lymphoma.The approval, for individuals aged 12 ...

Lymphoma care still leaves gaps—research aims for higher cure rates, longer remission, and fewer toxicities across B-, T-cell and Hodgkin.

The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.

Systemic failings in information sharing across Jersey's healthcare system led to "neglectful" and "distressing" delays to ...

In a study published today in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of ...

Curis, Inc. (NASDAQ:CRIS) Q4 2025 Earnings Call Transcript March 19, 2026 Curis, Inc. misses on earnings expectations. Reported EPS is $-0.5 EPS, expectations were $-0.436. Operator: Good afternoon, ...

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused ...

Management to host conference call today at 4:30 p.m. ETLEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology ...

Charlie endured six sessions of chemotherapy ...

On Saturday morning, the 20-year old college sophomore will be kicking off the first steps of her first road race — the Shamrock 8K at the Virginia Beach Oceanfront.